Author Correction: Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells

By sjmartinez • November 2, 2022

Khatri B, Tessneer KL, Rasmussen A, Aghakhanian F, Reksten TR, Adler A, Alevizos I, Anaya JM, Aqrawi LA, Baecklund E, Brun JG, Bucher SM, Eloranta ML, Engelke F, Forsblad-d'Elia H, Glenn SB, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kvarnström M, Kelly JA, Li H, Mandl T, Martín J, Nocturne G, Norheim KB, Palm Ø, Skarstein K, Stolarczyk AM, Taylor KE, Teruel M, Theander E, Venuturupalli S, Wallace DJ, Grundahl KM, Hefner KS, Radfar L, Lewis DM, Stone DU, Kaufman CE, Brennan MT, Guthridge JM, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner B, Rischmueller M, Witte T, Farris AD, Mariette X, Alarcon-Riquelme ME; PRECISESADS Clinical Consortium, Shiboski CH; Sjögren’s International Collaborative Clinical Alliance (SICCA), Wahren-Herlenius M, Ng WF; UK Primary Sjögren’s Syndrome Registry, Sivils KL, Adrianto I, Nordmark G, Lessard CJ. Author Correction: Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells. Nat Commun. 2022 Oct 31;13(1):6519. doi: 10.1038/s41467-022-34311-8. Erratum for: Nat Commun. 2022 Jul 27;13(1):4287. PMID: 36316359; PMCID: PMC9622850.

Tags: Publications, Rheumatology

Cognitive Behavioral Therapy for Autistic School-Aged Children with Interfering Anxiety: Impact on Caregiver-Defined Goals

Wood JJ, Rosenau KA, Muscatello V, Cooper K, Wood KS, Kendall PC, Storch EA. Cognitive Behavioral Therapy for Autistic School-Aged Children with Interfering Anxiety: Impact[...]

Antidepressant Medication Prescription and Incident Cardiovascular Disease in Women Veterans

Sumner JA, Dennis PA, Alvarez CA, Perkins A, Beckham JC, Ebrahimi R. Antidepressant Medication Prescription and Incident Cardiovascular Disease in Women Veterans. J Clin Psychiatry.[...]

Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy

Stopeck AT, Abu-Khalaf M, Borges V, Chmielowski B, Rao R, Xie B, Dudek AZ, Mina L, O'Shaughnessy J, Chisamore M, Mattson P, Gargano M, Cox[...]